STOCK TITAN
  1. Home
  2. News
  3. NMTC

NeuroOne Medical Technologies Corporation - $NMTC STOCK NEWS

Welcome to our dedicated page for NeuroOne Medical Technologies Corporation news (Ticker: $NMTC), a resource for investors and traders seeking the latest updates and insights on NeuroOne Medical Technologies Corporation stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect NeuroOne Medical Technologies Corporation's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of NeuroOne Medical Technologies Corporation's position in the market.

News
NeuroOne® Reports Fiscal Fourth Quarter and Full Fiscal Year 2023 Financial Results and Provides Corporate Update
Rhea-AI Summary
NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) announces fiscal fourth quarter and full fiscal year ended September 30, 2023 results. Q4 2023 product revenue of $742,000, up from $69,000 in Q4 2022. Full-year product revenue of $1,952,000, up from $171,000 in FY 2022. Completed $6M capital raise in July 2023. FDA clearance for OneRF Ablation System in December 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.05%
Tags
earnings
-
News
NeuroOne® Receives FDA 510(k) Clearance to Market its OneRF™ Ablation System
Rhea-AI Summary
NeuroOne Medical Technologies Corporation (NMTC) receives FDA 510(k) clearance for its OneRF Ablation System, the first FDA-cleared thin-film, sEEG-guided RF system capable of recording electrical activity and ablating nervous tissue with temperature control. The company targets a commercial launch in the first half of 2024, aiming to transform neurosurgery procedures and improve patient outcomes. The OneRF Ablation System is the company's third FDA 510(k)-cleared device, expanding its line of electrode technology to address patients requiring diagnostic brain mapping procedures as well as RF ablation using the same sEEG electrode. The current brain ablation market is estimated to be at least $100M worldwide and growing rapidly, with the potential to grow multifold based on large addressable patient populations with unmet clinical needs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.94%
Tags
clinical trial
-
News
NeuroOne® to Report Fourth Quarter and Fiscal Year 2023 Financial Results and Provide Corporate Update on December 14
Rhea-AI Summary
NeuroOne Medical Technologies Corporation (NMTC) to discuss Q4 and fiscal year 2023 financial results and corporate update
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.26%
Tags
conferences earnings
News
NeuroOne® Announces Patent Allowance for Drug Delivery Utilizing a Novel Neural Probe
Rhea-AI Summary
NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) announced that the USPTO issued a Notice of Allowance for a patent covering novel electrodes that can deliver a treatment agent to a patient's brain. The company's patent portfolio includes two other allowed patent applications, one issued U.S. patent, eight pending U.S. applications, and several foreign applications covering thin-film electrode technologies. CEO Dave Rosa highlighted the importance of these allowances in advancing the company's efforts to partner with biopharma companies for combination devices.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.33%
Tags
none
-
News
NeuroOne® Appoints Medtech Executive Christopher R. Volker as Chief Operating Officer and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) announced the appointment of Christopher R. Volker as Chief Operating Officer, strengthening the management team. Mr. Volker brings extensive experience from Abbott Laboratories and Cardiovascular Systems, Inc., with a focus on international commercial expansion and therapy development. The company also disclosed an equity award under the Inducement Plan for Mr. Volker.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.13%
Tags
management
-
News
NeuroOne® Provides Progress Update on FDA 510(k) Submission for OneRF™ Ablation System
Rhea-AI Summary
NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) responded to FDA questions on its OneRF Ablation System, expecting feedback in 30 days. The system offers transformative improvement in neurosurgery, combining diagnostic and therapeutic capabilities with potential cost reduction.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.49%
Tags
none
News
NeuroOne® to Present at the ThinkEquity Conference on October 19, 2023
Rhea-AI Summary
NeuroOne Medical Technologies to present at ThinkEquity Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.38%
Tags
conferences
-
News
NeuroOne® to Present at the H.C. Wainwright 25th Annual Global Investment Conference
Rhea-AI Summary
NeuroOne to present at H.C. Wainwright Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.01%
Tags
conferences
-
News
NeuroOne® Reports Third Quarter Fiscal Year 2023 Financial Results and Provides Corporate Update
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.76%
Tags
earnings
News
NeuroOne® to Report Third Quarter Fiscal Year 2023 Financial Results and Provide a Corporate Update on August 14
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.9%
Tags
conferences earnings
Stock NMTC logo
NeuroOne Medical Technologies Corporation

Nasdaq:NMTC

NMTC Rankings

#5042 Ranked by Market Cap
#1989 Ranked by Stock Gains
N/A Ranked by Dividends

NMTC Stock Data

27.49M
19.57M
12.2%
25.75%
1.41%
Surgical Appliance and Supplies Manufacturing
Manufacturing
Link
United States of America
EDEN PRAIRIE

About NMTC

neuroone medical technologies corporation operates as a medical technology company. it focuses on the development and commercialization of thin film electrode technology for continuous electroencephalogram (ceeg) and stereoelectroencephalography (seeg) recording, spinal cord stimulation, brain stimulation, and ablation solutions for patients suffering from epilepsy, parkinson's disease, dystonia, essential tremors, and other related brain related disorders. the company is based in eden prairie, minnesota.